|
|
Volumn 5, Issue 3, 1999, Pages 255-256
|
|
In utero gene therapy: The case against
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CELL DIFFERENTIATION;
COST BENEFIT ANALYSIS;
FETUS DEVELOPMENT;
FOOD AND DRUG ADMINISTRATION;
GENE AMPLIFICATION;
GENE EXPRESSION;
GENE MUTATION;
GENE THERAPY;
NOTE;
PRENATAL DIAGNOSIS;
PRIORITY JOURNAL;
RISK FACTOR;
ANIMAL EXPERIMENTATION;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
FEDERAL GOVERNMENT;
FETAL RESEARCH;
FETAL THERAPY;
GENETIC DISORDERS;
GENETICS AND REPRODUCTION;
GOVERNMENT REGULATION;
RECOMBINANT DNA ADVISORY COMMITTEE;
RISKS AND BENEFITS;
UNITED STATES;
ADVISORY COMMITTEES;
ANIMAL EXPERIMENTATION;
FEDERAL GOVERNMENT;
FEMALE;
FETAL RESEARCH;
GENE THERAPY;
GENETIC DISEASES, INBORN;
GOVERNMENT REGULATION;
HUMANS;
RISK ASSESSMENT;
UTERUS;
|
|
EID: 0033021870
PISSN: 10788956
EISSN: None
Source Type: Journal
DOI: 10.1038/6457 Document Type: Note |
|
Times cited : (35)
|
|
References (0)
|
